Business Wire

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

Share

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of LIVMARLI® (maralixibat) oral solution for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients three months of age and older. The CHMP also concluded that LIVMARLI in PFIC brings significant clinical benefit based on improved efficacy and a major contribution to patient care compared to the existing approved treatment for PFIC. The CHMP positive opinion is the scientific recommendation to the European Commission for marketing authorization in Europe.

In addition, the Committee for Orphan Medicinal Products (COMP), has also recommended maintenance of Orphan Drug Designation for LIVMARLI in PFIC. The European Commission’s endorsement of the CHMP and COMP opinions is expected in the third quarter of 2024.

“The positive and favorable opinions by both CHMP and COMP recognizes the potential of LIVMARLI in treating patients with PFIC in Europe, underscoring the compelling long-term data collected in the largest PFIC study across a broad range of genetic types,” said Chris Peetz, chief executive officer at Mirum. “Further, we are thrilled that, if approved by the European Commission, the PFIC community will have a treatment option that has been shown to significantly improve key liver health parameters starting from three months of age.”

The CHMP and COMP opinions are based on data from the Phase 3 MARCH study, the largest randomized trial conducted in PFIC, with 93 patients across a range of genetic PFIC types, including PFIC1, PFIC2, PFIC3, PFIC4, PFIC6, and unidentified mutational status.

LIVMARLI is currently approved in Europe for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older. In the United States, LIVMARLI is approved for the treatment of cholestatic pruritus in patients with ALGS three months of age and older and for cholestatic pruritus in patients with PFIC five years of age and older. LIVMARLI is also approved in other regions globally. Mirum has submitted a supplemental new drug application (sNDA) to introduce a higher concentration formulation of LIVMARLI, used during the MARCH study, to enable label expansion for younger patients with PFIC in the United States later this year.

About Progressive Familial Intrahepatic Cholestasis

Progressive familial intrahepatic cholestasis (PFIC) is a rare genetic disorder that causes progressive liver disease typically leading to liver failure. In people with PFIC, liver cells are less able to secrete bile. The resulting buildup of bile causes liver disease in affected individuals. Signs and symptoms of PFIC typically begin in infancy. Patients experience severe itching, jaundice, failure to grow at the expected rate (failure to thrive), and an increasing inability of the liver to function (liver failure). The disease is estimated to affect one in every 50,000 to 100,000 births in the United States and Europe. More than six types of PFIC have been genetically identified, all of which are similarly characterized by impaired bile flow and progressive liver disease.

About LIVMARLI® (maralixibat) oral solution

LIVMARLI® (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) three months of age and older and for progressive familial intrahepatic cholestasis (PFIC) five years of age and older.

LIVMARLI is also the only approved IBAT inhibitor approved by the European Commission for the treatment of cholestatic pruritus in patients with ALGS two months and older, and by Health Canada for the treatment of cholestatic pruritus in ALGS. For more information for U.S. residents, please visit LIVMARLI.com.

LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS and PFIC. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website.

IMPORTANT SAFETY INFORMATION

Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein.

LIVMARLI can cause side effects, including:

Liver injury. Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal.

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with Alagille syndrome and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects.

US Prescribing Information
EU SmPC
Canadian Product Monograph

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients five years of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential benefits of LIVMARLI and perceived superiority against other products, the marketing authorisation application pending with the European Commission and planned regulatory submissions in other countries. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “will,” “could,” “would,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of the COVID-19 pandemic, and the other risks described in Mirum’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.A further description of risks and uncertainties can be found in Mirum’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors,” as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Erin Murphy
media@mirumpharma.com

Investor Contact:
Andrew McKibben
investors@mirumphama.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Belkin Achieves Carbon Neutrality in Scope 1 and Scope 2 Emissions21.4.2025 10:00:00 EEST | Press release

Belkin, a leading consumer electronics brand for 40 years, today published its 2024 Impact Report, announcing its milestone achievement of carbon neutrality in scope 1 and scope 2 emissions, and underscoring its commitment to sustainability and corporate responsibility. With bold progress in carbon reduction and sustainable product design, Belkin remains steadfast in its commitment to finding more responsible ways to build products that enhance lives while preserving the planet for future generations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421326773/en/ Belkin achieves carbon neutrality in scope 1 and scope 2 emissions “Belkin recently surpassed a monumental milestone: over 1 billion products sold globally. As we reflect on this achievement, we recognize that with scale comes a profound responsibility – to our customers, to the planet, and to future generations,” said Steven Malony, CEO of Belkin. “As we reflect o

Seven HKTDC Mega Events Showcase Asia’s Creative Hub20.4.2025 08:51:00 EEST | Press release

The Hong Kong Trade Development Council (HKTDC) is hosting seven mega events, including Hong Kong Gifts & Premium Fair, Home InStyle and Fashion InStyle (27-30 April at the Hong Kong Convention and Exhibition Centre, HKCEC); the Hong Kong International Printing & Packaging Fair and DeLuxe PrintPack Hong Kong (held concurrently at AsiaWorld-Expo); and the Hong Kong International Licensing Show and Asian Licensing Conference (28-30 April at the HKCEC). The events are set to draw some 6,000 exhibitors from more than 30 countries and regions, serving as a bridge connecting Hong Kong's creative industries with Mainland China and international markets while reinforcing the city’s positioning as a regional creative hub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250414024775/en/ The HKTDC is hosting seven vibrant events spanning lifestyle products and the licensing sector in late April, including the Hong Kong Gifts & Premium F

Qualcomm Announces Quarterly Cash Dividend18.4.2025 16:00:00 EEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on June 26, 2025, to stockholders of record at the close of business on June 5, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business

Kinaxis Launches Tariff Response Solution to Help Supply Chains Adapt to Disruption with Confidence17.4.2025 20:30:00 EEST | Press release

As ongoing tariff pressures and trade uncertainty continue to reshape global supply chains, Kinaxis® (TSX:KXS), the leader in real-time supply chain orchestration, today launched Kinaxis Tariff Response - a new offering that helps companies simulate tariff exposure, run strategic scenarios, and make data-informed decisions quickly. Built on the company’s AI-powered Maestro™ platform and delivered by Kinaxis supply chain experts, the service can be live in as few as 21 days, giving planners access to tariff modeling without the cost or complexity of building it internally. The solution meets rising demand for scenario planning - providing a faster, more accessible way for companies to shift from reactive firefighting to proactive orchestration. While AI-powered what-if scenario planning has long been a core capability of Maestro, Kinaxis Tariff Response builds on that foundation with a focused solution for trade disruption. It combines tariff-specific inputs, sourcing logic, pricing lev

CORRECTING and REPLACING MultiSafepay Supporting 20,000 SMEs to Scale Through Payment Integration and Digitisation with Antom Technology Engine17.4.2025 20:07:00 EEST | Press release

Seventh paragraph, first sentence should read: Today, 8% of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments. (instead of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments.). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417858076/en/ Ant International’s new office in Amsterdam City Centre will house MultiSafepay’s operations and enable further collaboration between its business pillars. The updated release reads: MULTISAFEPAY SUPPORTING 20,000 SMES TO SCALE THROUGH PAYMENT INTEGRATION AND DIGITISATION WITH ANTOM TECH

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye